stoxline Quote Chart Rank Option Currency Glossary
  
G1 Therapeutics, Inc. (GTHX)
2.67  -0.11 (-3.96%)    06-17 16:00
Open: 2.8
High: 2.84
Volume: 602,599
  
Pre. Close: 2.78
Low: 2.65
Market Cap: 140(M)
Technical analysis
2024-06-17 5:23:51 PM
Short term     
Mid term     
Targets 6-month :  4.79 1-year :  5.84
Resists First :  4.1 Second :  5
Pivot price 3.07
Supports First :  2.65 Second :  2.2
MAs MA(5) :  2.83 MA(20) :  3.38
MA(100) :  3.8 MA(250) :  2.78
MACD MACD :  -0.4 Signal :  -0.4
%K %D K(14,3) :  4.6 D(3) :  4.8
RSI RSI(14): 24.6
52-week High :  6.13 Low :  1.08
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ GTHX ] has closed above bottom band by 3.9%. Bollinger Bands are 52.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 2.84 - 2.86 2.86 - 2.88
Low: 2.62 - 2.63 2.63 - 2.65
Close: 2.64 - 2.67 2.67 - 2.7
Company Description

G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, a (CDK) 4/6 inhibitor that is in Phase III clinical trials for patients with first line colorectal cancer; Phase III clinical trial for the treatment of first line triple negative breast cancer; Phase II clinical trial for patients with first line bladder cancer; Phase II clinical trial for patients with combination with the antibody-drug conjugate; and Phase II clinical trial for the treatment of neoadjuvant breast cancer. In addition, the company develops lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase IIa clinical trials for the treatment of estrogen receptor-positive and HER2-negative breast cancer. The company has a license agreement with EQRx, Inc. and Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat any indication in humans, as well as Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. for the development and commercialization of trilaciclib for any indication in humans through parenteral delivery, and ARC Therapeutics for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.

Headline News

Mon, 17 Jun 2024
G1 Therapeutics, Inc. (NASDAQ:GTHX) Short Interest Update - MarketBeat

Thu, 13 Jun 2024
Needham & Company LLC Reiterates “Buy” Rating for G1 Therapeutics (NASDAQ:GTHX) - Defense World

Thu, 13 Jun 2024
Analyst Ratings For G1 Therapeutics - G1 Therapeutics (NASDAQ:GTHX) - Benzinga

Thu, 13 Jun 2024
Birchview Capital LP Sells 40000 Shares of G1 Therapeutics, Inc. (NASDAQ:GTHX) - Defense World

Fri, 07 Jun 2024
Shareholders May Not Be So Generous With G1 Therapeutics, Inc.'s (NASDAQ:GTHX) CEO Compensation And Here's Why - Simply Wall St

Tue, 28 May 2024
Little Excitement Around G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Revenues - Simply Wall St

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 52 (M)
Shares Float 44 (M)
Held by Insiders 10.5 (%)
Held by Institutions 33.8 (%)
Shares Short 3,590 (K)
Shares Short P.Month 2,420 (K)
Stock Financials
EPS -0.61
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.52
Profit Margin -36.5 %
Operating Margin -62.5 %
Return on Assets (ttm) -10.9 %
Return on Equity (ttm) -84.2 %
Qtrly Rev. Growth 11.8 %
Gross Profit (p.s.) 0
Sales Per Share 1.6
EBITDA (p.s.) -0.43
Qtrly Earnings Growth 0 %
Operating Cash Flow -18 (M)
Levered Free Cash Flow -5 (M)
Stock Valuations
PE Ratio -4.45
PEG Ratio 0
Price to Book value 5.03
Price to Sales 1.66
Price to Cash Flow -7.68
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android